Here's a look at some of the latest news regarding ophthalmic drugs and therapies from the past week.
- Quidel Corporation announced today it completed the acquisition of the InflammaDry® and AdenoPlus® diagnostic businesses from RPS Diagnostics — a developer and manufacturer of rapid, point-of-care (POC) diagnostic tests for the eye health and primary care markets — for approximately $14 million in cash. InflammaDry and AdenoPlus are reportedly rapid, lateral-flow based, POC products for the detection of infectious and inflammatory diseases and conditions of the eye.
- Avedro, Inc. announced the publication of one-year safety and efficacy data from the randomized, controlled pivotal Phase 3 clinical trials that supported the FDA approval of Avedro’s Photrexa Viscous (riboflavin 5’-phosphate in 20% dextran ophthalmic solution), Photrexa (riboflavin 5’-phosphate dextran ophthalmic solution) and KXL System for the treatment of progressive keratoconus. The clinical trials reportedly exceeded the primary efficacy endpoint of 1.00 D difference in Kmax over 1 year between the cross-linking treatment arm and the control group.
- Glaukos Corporation reported an analysis published in the Journal of Medical Economics evaluating various options for treating elevated intraocular pressure (IOP) in open-angle glaucoma patients showed that two iStent® Trabecular Micro-Bypass Stents had a lower projected average cumulative cost at five years than either selective laser trabeculoplasty (SLT) or topical glaucoma medication only.
- Tyrogenex announced that the Journal of the American Medical Association has published results from its Phase 1 dose-escalation study of its lead product candidate, X-82 (vorolanib). The research reportedly presents data evaluating the safety and preliminary efficacy of orally administered X-82 for the treatment of neovascular age-related macular degeneration (AMD).
- Sylentis announced the start of the first Phase III study, HELIX, with the investigational drug SYL1001 for the indication of dry eye syndrome. The company has reportedly agreed with the U.S. FDA on plans for the Phase III clinical program, which is designed to support the submission of a New Drug Application (NDA).
- Aldeyra Therapeutics, Inc. has enrolled the first patient into a Phase 2a clinical trial of topical ocular ADX-102 for the treatment of Dry Eye Disease (DED). The Phase 2a clinical trial will reportedly test three formulations of topical ocular ADX-102 over 28 days of dosing.
Like what you read? Follow OphthalmologyWeb to keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox.